Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES
- Jukema, J. Wouter
- Zijlstra, Laurien E.
- Bhatt, Deepak L.
- Bittner, Vera A.
- Diaz, Rafael
- Drexel, Heinz
- Goodman, Shaun G.
- Kim, Yong-Un
- Pordy, Robert
- Reiner, Željko
- Roe, Matthew T.
- Tse, Hung-Fat
- Montenegro Valdovinos, Pablo Carlos
- White, Harvey D.
- Zeiher, Andreas M.
- Szarek, Michael
- Schwartz, Gregory G.
- Steg, Philippe Gabriel
DOIAbstract
Background: Lowering of atherogenic lipoproteins, including low-density lipoprotein cholesterol (LDL-C), reduces the risk of ischemic stroke. However, concerns have been raised about very low LDL-C levels and a potential increased risk of hemorrhagic stroke. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome and elevated atherogenic lipoproteins, despite intensive statin therapy, targeting LDL-C levels of 25 to 50 mg/dL and avoiding sustained LDL-C <15 mg/dL. This prespecified analysis was designed to assess the effect of alirocumab on ischemic and hemorrhagic stroke. We hypothesized that for patients treated with alirocumab there would be a reduction in risk of ische...
Add to ORKG